$JAZZ
Jazz Pharmaceuticals PLC

2012 Q2 Form 10-Q Financial Statement

#000119312512341236 Filed on August 07, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2011 Q2
Revenue $124.2M $64.57M
YoY Change 92.41% 0.0%
Cost Of Revenue $12.30M $3.400M
YoY Change 261.76% 21.43%
Gross Profit $110.7M $60.09M
YoY Change 84.23% 0.0%
Gross Profit Margin 89.12% 93.07%
Selling, General & Admin $57.22M $22.09M
YoY Change 159.0% 29.2%
% of Gross Profit 51.69% 36.77%
Research & Development $2.321M $3.382M
YoY Change -31.37% -57.73%
% of Gross Profit 2.1% 5.63%
Depreciation & Amortization $16.00M $1.900M
YoY Change 742.11% -13.64%
% of Gross Profit 14.45% 3.16%
Operating Expenses $84.80M $30.71M
YoY Change 176.16% 13.31%
Operating Profit $39.43M $33.86M
YoY Change 16.44% 2.62%
Interest Expense -$1.481M -$657.0K
YoY Change 125.42% -86.02%
% of Operating Profit -3.76% -1.94%
Other Income/Expense, Net
YoY Change
Pretax Income $37.71M $33.20M
YoY Change 13.57% -618.78%
Income Tax $6.593M $0.00
% Of Pretax Income 17.49% 0.0%
Net Earnings $27.15M $33.20M
YoY Change -18.24% 0.0%
Net Earnings / Revenue 21.85% 51.42%
Basic Earnings Per Share $0.48 $0.81
Diluted Earnings Per Share $0.45 $0.71
COMMON SHARES
Basic Shares Outstanding 56.95M shares 41.21M shares
Diluted Shares Outstanding 60.55M shares 46.60M shares

Balance Sheet

Concept 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $154.5M $102.4M
YoY Change 50.88% 966.67%
Cash & Equivalents $154.5M $102.4M
Short-Term Investments $0.00 $102.0M
Other Short-Term Assets $13.51M $4.000M
YoY Change 237.7% 0.0%
Inventory $48.36M $4.700M
Prepaid Expenses $5.906M
Receivables $78.13M $25.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $300.4M $136.1M
YoY Change 120.75% 323.99%
LONG-TERM ASSETS
Property, Plant & Equipment $4.631M $600.0K
YoY Change 671.83% -33.33%
Goodwill $446.2M
YoY Change
Intangibles $927.4M
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.23M $200.0K
YoY Change 9513.0% -33.33%
Total Long-Term Assets $1.398B $57.30M
YoY Change 2338.92% -12.12%
TOTAL ASSETS
Total Short-Term Assets $300.4M $136.1M
Total Long-Term Assets $1.398B $57.30M
Total Assets $1.698B $193.4M
YoY Change 777.94% 98.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.51M $4.700M
YoY Change 634.15% -26.56%
Accrued Expenses $125.1M $26.70M
YoY Change 368.46% 64.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $4.000M
YoY Change -100.0% -45.95%
Long-Term Debt Due $23.75M $32.70M
YoY Change -27.37% 105.66%
Total Short-Term Liabilities $192.3M $81.30M
YoY Change 136.55% 44.4%
LONG-TERM LIABILITIES
Long-Term Debt $444.2M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.615M $10.50M
YoY Change -84.62% -57.32%
Total Long-Term Liabilities $445.8M $10.50M
YoY Change 4145.76% -81.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $192.3M $81.30M
Total Long-Term Liabilities $445.8M $10.50M
Total Liabilities $638.1M $91.80M
YoY Change 595.12% -19.19%
SHAREHOLDERS EQUITY
Retained Earnings -$295.1M
YoY Change
Common Stock $1.126B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $831.5M $101.6M
YoY Change
Total Liabilities & Shareholders Equity $1.698B $193.4M
YoY Change 777.94% 98.77%

Cashflow Statement

Concept 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income $27.15M $33.20M
YoY Change -18.24% 0.0%
Depreciation, Depletion And Amortization $16.00M $1.900M
YoY Change 742.11% -13.64%
Cash From Operating Activities $77.00M $37.50M
YoY Change 105.33% 237.84%
INVESTING ACTIVITIES
Capital Expenditures -$10.50M -$1.200M
YoY Change 775.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$550.7M $400.0K
YoY Change -137775.0% 300.0%
Cash From Investing Activities -$561.2M -$800.0K
YoY Change 70050.0% -33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 468.6M 700.0K
YoY Change 66842.86% -103.61%
NET CHANGE
Cash From Operating Activities 77.00M 37.50M
Cash From Investing Activities -561.2M -800.0K
Cash From Financing Activities 468.6M 700.0K
Net Change In Cash -15.60M 37.40M
YoY Change -141.71% -493.68%
FREE CASH FLOW
Cash From Operating Activities $77.00M $37.50M
Capital Expenditures -$10.50M -$1.200M
Free Cash Flow $87.50M $38.70M
YoY Change 126.1% 214.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
154543000
CY2012Q2 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
35100000
CY2012Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
575000000
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57536632 shares
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102396000
CY2012Q1 jazz Capital Redemption Reserve
CapitalRedemptionReserve
471000
CY2012Q2 us-gaap Goodwill
Goodwill
446236000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2807000
CY2012Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11571000
CY2012Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1126371000
CY2012Q2 us-gaap Other Assets Current
OtherAssetsCurrent
13508000
CY2012Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6078000
CY2012Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19226000
CY2012Q2 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
35300000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
82140000
CY2012Q2 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2923000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
831459000
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
892913000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4957000
CY2012Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
94000
CY2012Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4102000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
48500000
CY2012Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2461000
CY2012Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18873000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
69118000
CY2012Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7175000
CY2012Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
4164000
CY2012Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance On First Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
42500000
CY2012Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
45700000
CY2012Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5682000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5713000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6668000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
533905000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
34505000
CY2012Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5906000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2011000
CY2012Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1615000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4158000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295056000
CY2012Q2 us-gaap Assets
Assets
1697944000
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8140000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
542697000
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1260000
CY2011Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
524000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2012Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
185706000
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
78130000
CY2012Q2 us-gaap Inventory Net
InventoryNet
48355000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1697944000
CY2012Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1058000
CY2012Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154543000
CY2012Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
959546000
CY2012Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
927409000
CY2012Q2 us-gaap Noncurrent Assets
NoncurrentAssets
1397502000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5755000
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-388000
CY2012Q2 us-gaap Business Acquisition Contingent Consideration At Fair Value Noncurrent
BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent
35300000
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125080000
CY2012Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
871000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
75190000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
87313000
CY2012Q2 us-gaap Business Acquisition Contingent Consideration Potential Cash Payment
BusinessAcquisitionContingentConsiderationPotentialCashPayment
50000000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
192318000
CY2012Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
38175000
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7356000
CY2012Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
66633000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
300442000
CY2012Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
45247000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
30058000
CY2012Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6940000
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4631000
CY2012Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
23750000
CY2012Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
444190000
CY2012Q2 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
154543000
CY2012Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
35947000
CY2012Q2 jazz Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
994042000
CY2012Q2 jazz Sales Return Reserve
SalesReturnReserve
25690000
CY2012Q2 jazz Purchased Product Rights Liability Current
PurchasedProductRightsLiabilityCurrent
6972000
CY2012Q2 jazz Number Of Customers With Significant Accounts Receivable Balance
NumberOfCustomersWithSignificantAccountsReceivableBalance
5 Customer
CY2012Q2 jazz Entity Wide Accounts Receivable Major Customer Percentage
EntityWideAccountsReceivableMajorCustomerPercentage
0.71 pure
CY2012Q2 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000
CY2012Q2 jazz Capital Redemption Reserve
CapitalRedemptionReserve
471000
CY2012Q2 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
31713000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44794000
CY2011Q4 us-gaap Goodwill
Goodwill
38213000
CY2011Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2046000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
192788000
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14585000
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
157929000
CY2011Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
76000
CY2011Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1937000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
689000
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2439000
CY2011Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
4010000
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4021000
CY2011Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
43600000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5129000
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
75822000
CY2011Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1690000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1138000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349882000
CY2011Q4 us-gaap Assets
Assets
253573000
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34374000
CY2011Q4 us-gaap Inventory Net
InventoryNet
3909000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
10000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253573000
CY2011Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
763000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82076000
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
41000
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52000000
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14585000
CY2011Q4 us-gaap Noncurrent Assets
NoncurrentAssets
54442000
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-31000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34783000
CY2011Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
556000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52870000
CY2011Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1448000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7915000
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
37415000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
199131000
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6583000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1557000
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
157898000
CY2011Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11643000
CY2011Q4 jazz Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
52000000
CY2011Q4 jazz Sales Return Reserve
SalesReturnReserve
4302000
CY2011Q4 jazz Purchased Product Rights Liability Current
PurchasedProductRightsLiabilityCurrent
4500000
CY2011Q4 jazz Liability Under Government Settlement Current
LiabilityUnderGovernmentSettlementCurrent
7320000
CY2011Q4 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
12378000
us-gaap Operating Income Loss
OperatingIncomeLoss
56463000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-394000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
113367000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1616000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
55029000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-51000
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.21
us-gaap Share Based Compensation
ShareBasedCompensation
6563000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
202515000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-400000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
161000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2844000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61884000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2011000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-3350000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-476000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
57602000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1820000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46238000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2606000 shares
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2918000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.35
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7077000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2271000
us-gaap Operating Expenses
OperatingExpenses
58985000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1434000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40788000 shares
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-352000
us-gaap Revenues
Revenues
115448000
us-gaap Depreciation
Depreciation
189000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6563000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55029000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2250000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-11071000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1016000 shares
us-gaap Net Income Loss
NetIncomeLoss
55029000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42005000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3724000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
8332000
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.21
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3141000
jazz Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants
ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants
9411000
jazz Decrease In Liability Under Government Settlement
DecreaseInLiabilityUnderGovernmentSettlement
-3976000
jazz Royalties And Contract Revenues
RoyaltiesAndContractRevenues
2081000
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnology
6179000
dei Trading Symbol
TradingSymbol
JAZZ
dei Entity Registrant Name
EntityRegistrantName
Jazz Pharmaceuticals plc
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001232524
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Income Loss
OperatingIncomeLoss
68644000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-309000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
235646000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11363000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
542531000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54469000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
31988000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1191000
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
1.34
us-gaap Share Based Compensation
ShareBasedCompensation
8539000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
320848000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2494000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations of Risk</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents and marketable securities. Our investment policy permits investments in debt securities issued by the U.S. government or its agencies, corporate bonds or commercial paper issued by U.S. corporations, certain money market mutual funds, certain repurchase agreements, and tax-exempt obligations of states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to hospitals, pharmaceutical wholesale distributors and a specialty pharmaceutical distribution company, primarily in the United States, and to other international distributors. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June&#xA0;30, 2012, five customers accounted for 71% of gross accounts receivable and one customer, Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, accounted for 46% of gross accounts receivable.&#xA0;As of December&#xA0;31, 2011, Express Scripts accounted for 79% of gross accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We rely on certain sole suppliers for drug substance and certain sole manufacturing partners for certain of our marketed products and product candidates.</font></p> </div>
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1633000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.181 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
101264000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-478734000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
258000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
250000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
72467000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5390000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59319000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2249000 shares
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7427000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-388000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-357000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.99
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6280000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
450428000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
23000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
37443000
us-gaap Revenues
Revenues
237953000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25299000
us-gaap Operating Expenses
OperatingExpenses
169309000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1450000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
6238000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55437000 shares
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-806000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
450916000
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
quarterly
us-gaap Depreciation
Depreciation
415000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-139000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
-200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8539000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
66936000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
81246000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9500000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
75694000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1079000 shares
us-gaap Net Income Loss
NetIncomeLoss
54826000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
6238000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
107637000
CY2011Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22094000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12110000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-491000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></p> </div>
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29264000
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
1.25
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16339000
jazz Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants
ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants
18573000
jazz Decrease In Liability Under Government Settlement
DecreaseInLiabilityUnderGovernmentSettlement
-7320000
jazz Royalties And Contract Revenues
RoyaltiesAndContractRevenues
2307000
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2011Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1862000
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnology
26128000
jazz Fair Value Inventory Step Up Adjustment
FairValueInventoryStepUpAdjustment
6380000
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
33859000
CY2011Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
63464000
CY2011Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
33202000
CY2011Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.02
CY2011Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
109490000
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.71
CY2011Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2821000 shares
CY2011Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46601000 shares
CY2011Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2571000 shares
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3382000
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
30708000
CY2011Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-657000
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41209000 shares
CY2011Q2 us-gaap Revenues
Revenues
64567000
CY2011Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3415000
CY2011Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33202000
CY2011Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
1137000
CY2011Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1372000 shares
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
33202000
CY2011Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.02
CY2011Q2 jazz Royalties And Contract Revenues
RoyaltiesAndContractRevenues
1103000
CY2011Q2 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnology
3370000
CY2012Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
400000
CY2012Q1 jazz Shares Sold In Secondary Offering
SharesSoldInSecondaryOffering
7900000 shares
CY2012Q1 jazz Proceeds From Secondary Offering
ProceedsFromSecondaryOffering
390700000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
35459000
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
128310000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26754000
CY2012Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.70
CY2012Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
166289000
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2012Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1440000 shares
CY2012Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195 pure
CY2012Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
240000
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60554000 shares
CY2012Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2162000 shares
CY2012Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-388000
CY2012Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-391000
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2321000
CY2012Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
17000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
94080000
CY2012Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1481000
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56952000 shares
CY2012Q2 us-gaap Revenues
Revenues
129539000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5258000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33738000
CY2012Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
40074000
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1522000 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
27145000
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60638000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6593000
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20000
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15751000
CY2012Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.66
CY2012Q2 jazz Royalties And Contract Revenues
RoyaltiesAndContractRevenues
1229000
CY2012Q2 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnology
15370000

Files In Submission

Name View Source Status
0001193125-12-341236-index-headers.html Edgar Link pending
0001193125-12-341236-index.html Edgar Link pending
0001193125-12-341236.txt Edgar Link pending
0001193125-12-341236-xbrl.zip Edgar Link pending
d369113d10q.htm Edgar Link pending
d369113dex1010.htm Edgar Link pending
d369113dex102.htm Edgar Link pending
d369113dex103.htm Edgar Link pending
d369113dex104.htm Edgar Link pending
d369113dex105.htm Edgar Link pending
d369113dex106.htm Edgar Link pending
d369113dex107.htm Edgar Link pending
d369113dex108.htm Edgar Link pending
d369113dex109.htm Edgar Link pending
d369113dex311.htm Edgar Link pending
d369113dex312.htm Edgar Link pending
d369113dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
jazz-20120630.xml Edgar Link completed
jazz-20120630.xsd Edgar Link pending
jazz-20120630_cal.xml Edgar Link unprocessable
jazz-20120630_def.xml Edgar Link unprocessable
jazz-20120630_lab.xml Edgar Link unprocessable
jazz-20120630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending